Merck has launched a BioContinuum Platform to optimize the manufacturing of biotherapeutic drugs by boosting efficiency, simplifying processes and increasing quality and consistency.21 Nov 2018
The new BioContinuum Platform from Merck KGaA is a solution for continuous production and purification (bioprocessing) of biopharmaceuticals. It integrates what are typically batch-based, separate steps into an end-to-end process, enabling a continuous flow - from adding raw materials right through to product harvesting, purification and testing.
"Merck's new, adaptive platform of products, applications and expertise will enable customers to get urgently needed new treatments to patients faster and more cost-effectively than ever before," says Udit Batra, member of the Merck Executive Board and CEO Life Science. "Our unique and holistic approach to next-generation bioprocessing means we can harness the benefits of process intensification throughout the entire process chain - something we cannot achieve by focusing on one area at a time." The Merck BioContinuum Platform covers a variety of different areas, ranging from products and technical documentation to the company's vast know-how in terms of application-specific and technical support.
Merck KGaA (64293 Darmstadt, Germany)
Interested in news about exhibitors, top offers and trends in the industry?
Your web browser is outdated. Update your browser for more security, speed and optimal presentation of this page.Update Browser